secwatch.observer — SEC 8-K summary
======================================

Issuer:     PTC THERAPEUTICS, INC. (PTCT)
CIK:        0001070081
Form:       8-K
Filed at:   2025-07-28T23:59:59+00:00
Accession:  0001558370-25-009663
Event type: regulatory
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PTC Therapeutics receives FDA approval for Sephience (sepiapterin) to treat PKU in patients 1 month and older
--------------------------------------------------------------------------------

- FDA approved Sephience for hyperphenylalaninemia in adult/pediatric patients ≥1 month with sepiapterin-responsive PKU.
- Approval based on Phase 3 APHENITY trial and long-term extension data showing significant efficacy and safety.
- Broad labeling includes all disease subtypes; PTC CEO states Sephience could become standard of care.
- SEPHIENCE recently received EU marketing authorization; reviews ongoing in Japan, Brazil and other countries.
- PTC to host conference call July 28 at 5pm ET to discuss approval.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070081/000155837025009663/0001558370-25-009663-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070081/000155837025009663/tmb-20250728x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-009663

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer